Combined Schisandrin B and Temozolomide Treatment Induces Mitochondrial Apoptosis in Glioma Cells
Authors:
Open Access
- 27 November 2025
- journal article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (11) , 46410
Abstract
Background: Temozolomide (TMZ) is a standard chemotherapeutic agent for glioma, but prolonged use frequently leads to drug resistance, reducing its therapeutic efficacy. Schisandrin B (Sch B), a lignan isolated from Schisandra chinensis, demonstrates promising anti-neoplastic activity. This study investigated the synergistic effects of Sch B and TMZ on U87 glioma cells to explore their combined influence on cell viability, apoptosis, and mitochondrial function. Methods: U87 glioma cells were treated with Sch B, TMZ, or their combination. Cell viability was assessed using MTT assays. Apoptosis was evaluated by Hoechst staining and flow cytometry, while JC-1 staining and Western blotting were used to assess mitochondrial membrane potential, oxidative stress markers, and apoptosis-related proteins. Cell cycle analysis and pre-treatment with Z-VAD-FMK were performed to confirm pathway involvement. Results: Combination treatment significantly reduced cell viability (54.14%) compared to TMZ (72.47%) or Sch B (70.4%) alone. Flow cytometry indicated elevated apoptosis (22.3%) in the combination group. JC-1 staining and protein expression analyses revealed mitochondrial depolarization, cytochrome c release, activation of caspase-3 and -9, and a decreased Bcl-2/Bax ratio. The combined treatment induced G2/M cell cycle arrest via p53/p21 activation and increased oxidative stress. Pre-treatment with Z-VAD-FMK partially reversed these effects, confirming caspase-dependent mitochondrial apoptosis. Conclusions: Sch B enhances TMZ-induced cytotoxicity in U87 glioma cells by promoting mitochondrial dysfunction, oxidative stress, and caspase-mediated apoptosis. These findings suggest that Sch B may serve as a promising adjuvant to improve the efficacy of TMZ-based glioma therapy, warranting further validation in resistant and in-vivo models.Keywords
Funding Information
- Jilin Province Science and technology development plan (YDZJ202101ZYTS095)
- Foundation of Innovation and Entrepreneurship Program of college students in Jilin Province (2021005)
This publication has 32 references indexed in Scilit:
- Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibitionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Role of COL6A2 in malignant progression and temozolomide resistance of gliomaCellular Signalling, 2022
- Schisandra B, a representative lignan from Schisandra chinensis, improves cisplatin‐induced toxicity: An in vitro studyPhytotherapy Research, 2022
- Anti-colon cancer activity of water-soluble polysaccharides extracted from Gloeostereum incarnatum via Wnt/β-catenin signaling pathwayFood Science and Human Wellness, 2021
- Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathwayBiomedicine & Pharmacotherapy, 2015
- Tumor suppressor p53 and its mutants in cancer metabolismCancer Letters, 2015
- Delayed growth of glioma by a polysaccharide from Aster tataricus involve upregulation of Bax/Bcl-2 ratio, activation of caspase-3/8/9, and downregulation of the AktTumor Biology, 2013
- Natural products for cancer prevention associated with Nrf2–ARE pathwayFood Science and Human Wellness, 2013
- Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signalingCellular Signalling, 2012
- Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in ratsBiopharmaceutics & Drug Disposition, 2010